<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03221933</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 030 CT-II</org_study_id>
    <nct_id>NCT03221933</nct_id>
  </id_info>
  <brief_title>A Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for SGA</brief_title>
  <official_title>Phase Ⅱ Clinical Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for Gestational Age(SGA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To preliminary assess the efficacy and safety of recombinant human growth hormone injection
      on the treatment of small for gestational age (SGA), and determine the best dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2009</start_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Height standard deviation score for chronological age (Ht SDSCA)</measure>
    <time_frame>26 weeks</time_frame>
    <description>HtSDSCA = (height-reference mean for CA) / reference SD for CA (refers to the height value at particular timepoint)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height standard deviation score for chronological age (Ht SDSCA)</measure>
    <time_frame>52 weeks</time_frame>
    <description>HtSDSCA = (height-reference mean for CA) / reference SD for CA (refers to the height value at particular timepoint)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height standard deviation score for chronological age (Ht SDSCA)</measure>
    <time_frame>78 weeks</time_frame>
    <description>HtSDSCA = (height-reference mean for CA) / reference SD for CA (refers to the height value at particular timepoint)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height standard deviation score for chronological age (Ht SDSCA)</measure>
    <time_frame>104 weeks</time_frame>
    <description>HtSDSCA = (height-reference mean for CA) / reference SD for CA (refers to the height value at particular timepoint)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ΔHtSDSCA</measure>
    <time_frame>26 weeks， 52 weeks，78 weeks and 104 weeks</time_frame>
    <description>Change in height SDS for chronological age (Ht SDSCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HV</measure>
    <time_frame>26 weeks， 52 weeks，78 weeks and 104 weeks</time_frame>
    <description>Change in annualized height velocity (HV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone age maturation</measure>
    <time_frame>26 weeks， 52 weeks，78 weeks and 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mole ratio of IGF-1 and IGFBP-3</measure>
    <time_frame>26 weeks， 52 weeks，78 weeks and 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PAH</measure>
    <time_frame>26 weeks， 52 weeks，78 weeks and 104 weeks</time_frame>
    <description>Change in prediction of adult height (PAH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in obesity prevalence</measure>
    <time_frame>26 weeks， 52 weeks，78 weeks and 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overweight</measure>
    <time_frame>26 weeks， 52 weeks，78 weeks and 104 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Small for Gestational Age Infant</condition>
  <arm_group>
    <arm_group_label>Somatropin Injection low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.23mg/kg /wk，inject for seven divided doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Somatropin Injection high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.46mg/kg /wk，inject for seven divided doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Somatropin Injection low dose group</intervention_name>
    <description>0.23mg/kg /wk，inject for seven divided doses</description>
    <arm_group_label>Somatropin Injection low dose group</arm_group_label>
    <arm_group_label>Somatropin Injection high dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Somatropin Injection high dose group</intervention_name>
    <description>0.46mg/kg /wk，inject for seven divided dose</description>
    <arm_group_label>Somatropin Injection low dose group</arm_group_label>
    <arm_group_label>Somatropin Injection high dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of small for gestational age, SGA.

          -  Chronological age between 2-6.5 years in girls and 2-7.5 years in boys. Both genders.

          -  Prepubertal stage (Tanner I).

          -  Without catch-up growth in two years after birth.

          -  Height was lower than the mean -2SD of the values of normal children of the same age
             and gender when participating in the study.

          -  A GH peak concentration ＞10µg/L in a provocative test within a year before participate
             in the study.

          -  Bone age＜Chronological age+1.

          -  Normal glucose regulation：Fasting blood-glucose &lt; 5.6mmol/L and 2-hour postprandial
             blood glucose&lt; 7.8mmol/L.

          -  Gestational age≥Gestational age≥ 36weeks + 4days.

          -  Never accepted growth hormone treatment.

          -  The subjects and their guardians signed informed consent.

        Exclusion Criteria:

          -  Subjects with Liver and renal insufficiency (ALT &gt; 2 times of upper limit of normal
             value, Cr&gt; upper limit of normal value).

          -  Patients with positive for antibodies to hepatitis B core (anti-HBc), hepatitis B
             surface antigen (HBsAg) or hepatitis B e antigen (HBeAg)。

          -  Known highly allergic constitution or allergic to the test drug.

          -  Subjects with diabetes, severe cardiopulmonary and pulmonary disease, and
             hematological diseases, malignant tumors, or systemic infection, immunocompromised
             patients and patients with psychosis.

          -  Subjects with other types of abnormal growth and development, such as Turner syndrome,
             constitutional delay of puberty, Laron syndrome, growth hormone receptor deficiency.

          -  Subjects who have received the treatment of Somatropin or took part in other clinical
             trial study within 3 months.

          -  Other conditions which in the opinion of the investigator preclude enrollment into the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>90 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoping Luo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital with Nanjing Medical Universit</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital of Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>December 10, 2017</last_update_submitted>
  <last_update_submitted_qc>December 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

